Eisai E2609 (Elenbecestat) in MCI / Mild Alzheimer’s Disease
What is the Eisai Study?
This is a two-year, randomized, double-blind study enrolling approximately 1,330 participants across 350 sites worldwide. The participants for this study must be between the ages 50 – 85 and have a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). An open-label extension phase will be available to participants who complete the full two years of the treatment phase.
What is the purpose of the Eisai Study?
The purpose of this study is to test the safety and effectiveness of an investigational drug, elenbecestat (E2609), in treating participants who have mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). Participants in the study will be randomly assigned to receive either the investigational drug or placebo, which is an inactive substance designed to look like a medication, but has no effect. Both the investigational drug and placebo will be administered as an oral tablet taken daily.
Men and women between the ages of 50 – 85 who have a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). All participants must have a study partner who spends at least 8 hours per week with them and would be able to support them throughout the duration of the study. There is a screening phase during which you will answer several questionnaires to help determine whether you are eligible.
If you are interested in learning more about the Eisai study, please call (401) 455-6402 or send an e-mail firstname.lastname@example.org. Ask about the “Eisai Trial.”